BioMarin’s Next Chapter: ‘A Financial Growth Story’

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.

BioMarin Pharmaceutical Inc. is maturing as a company, and the focus is on growing profitability while advancing multiple products in the pipeline at the same time. The firm’s management team outlined BioMarin’s near and longer-term R&D strategy to investors during an R&D day in New York on 12 September.

Key Takeaways

  • BioMarin outlined its growth strategy to investors during an R&D day.

“Biomarin is turning into a financial growth story, whereby we have the luxury of being able to grow the profitability...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Merck’s Winrevair Approved For PAH In Europe As Initial US Launch Progresses

 
• By Mandy Jackson

Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.

BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team

 
• By Mandy Jackson

The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.

Gene Therapy Patient Pipeline Builds, But Slowly, In Q2

 
• By Jessica Merrill

Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area. 

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.